Miltefosine Zentaris.
Zentaris (formerly Asta Medica) has developed and launched miltefosine, a phospholipid derivative, in various European countries [173324], [254947] and in Brazil in 1997 [332428], [366795] as a treatment for breast cancer. As of January 2002, phase III trials for treatment of leishmaniaisis were ongoing [435767]. In February 1999, Lehman Brothers predicted miltefosine would be launched for treatment of leishmaniasis in 2002, with peak sales expected in 2010 [319225].